Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 597

1.
2.
3.

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

Pershadsingh HA.

Expert Opin Investig Drugs. 2004 Mar;13(3):215-28. Review.

PMID:
15013941
4.
5.

Can PPARgamma agonists have a role in the management of obesity-related hypertension?

Chetty VT, Sharma AM.

Vascul Pharmacol. 2006 Jul;45(1):46-53. Epub 2006 May 19. Review.

PMID:
16713364
6.

Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

Belvisi MG, Hele DJ, Birrell MA.

Eur J Pharmacol. 2006 Mar 8;533(1-3):101-9. Epub 2006 Feb 3. Review.

PMID:
16458290
7.

PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Gross B, Staels B.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. Review.

PMID:
18054742
8.

Insulin resistance and PPAR insulin sensitizers.

Bhatia V, Viswanathan P.

Curr Opin Investig Drugs. 2006 Oct;7(10):891-7. Review.

PMID:
17086933
9.
10.

Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.

Higgins LS, Depaoli AM.

Am J Clin Nutr. 2010 Jan;91(1):267S-272S. doi: 10.3945/ajcn.2009.28449E. Epub 2009 Nov 11. Review.

PMID:
19906796
11.

Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.

Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.

Mol Pharmacol. 2012 Jul;82(1):68-79. doi: 10.1124/mol.111.076679. Epub 2012 Apr 10.

12.
13.

[Insulin sensitizing drugs].

Smahelová A.

Vnitr Lek. 2009 Apr;55(4):425-8. Review. Czech.

PMID:
19449763
14.

Thiazolidinediones and PPARγ agonists: time for a reassessment.

Cariou B, Charbonnel B, Staels B.

Trends Endocrinol Metab. 2012 May;23(5):205-15. doi: 10.1016/j.tem.2012.03.001. Epub 2012 Apr 17. Review.

PMID:
22513163
15.

Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.

Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV.

Expert Opin Investig Drugs. 2010 Apr;19(4):489-512. doi: 10.1517/13543781003640169. Review.

PMID:
20367191
16.

Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.

Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Oct;5(5):377-86. Review.

PMID:
16248830
17.

Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.

Blaschke F, Caglayan E, Hsueh WA.

Endocrinol Metab Clin North Am. 2006 Sep;35(3):561-74, ix. Review.

PMID:
16959586
18.

PPAR ligands: are they potential agents for cardiovascular disorders?

Balakumar P, Rose M, Singh M.

Pharmacology. 2007;80(1):1-10. Epub 2007 May 10. Review.

PMID:
17496434
19.

New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.

Alarcón de la Lastra C, Sánchez-Fidalgo S, Villegas I, Motilva V.

Curr Pharm Des. 2004;10(28):3505-24. Review.

PMID:
15579048
20.

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

Fiévet C, Fruchart JC, Staels B.

Curr Opin Pharmacol. 2006 Dec;6(6):606-14. Epub 2006 Sep 14. Review.

PMID:
16973418

Supplemental Content

Support Center